Lomitapide
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 342 publications
New and Emerging Therapeutic Targets for ApoB-Containing Particles Lowering.
Journal: Circulation research
Published: June 04, 2026
Drugs for hypercholesterolemia.
Journal: The Medical letter on drugs and therapeutics
Published: June 01, 2026
Computational Drug Repurposing Predicts FDA-Approved Drugs as Potential Inhibitors of Chikungunya Virus nsP2 Protease.
Journal: The journal of physical chemistry. B
Published: May 29, 2026
Current and Future Perspectives of LDL-C Lowering Therapies 2026.
Journal: Journal of atherosclerosis and thrombosis
Published: May 27, 2026
Homozygous familial hypercholesterolemia (HoFH) in Canada.
Journal: Atherosclerosis
Published: March 20, 2026
The evaluation of plozasiran for the treatment of familial chylomicronemia syndrome.
Journal: Expert review of endocrinology & metabolism
Published: March 20, 2026
Loss of KLF15 expression characterizes proximal tubule injury in cisplatin-induced acute kidney injury: A multi-omics study.
Journal: Current research in toxicology
Published: January 14, 2026
Lomitapide reduces viability and clonogenicity in hepatocellular carcinoma cells but enhances xenograft growth: The importance of the tumor microenvironment.
Journal: The Journal of pharmacology and experimental therapeutics
Published: January 12, 2026
Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association.
Journal: Journal of clinical lipidology
Published: January 07, 2026
Modulating IL-1β-induced pro-atherogenic endothelial responses through drug repurposing.
Journal: Inflammopharmacology
Published: December 20, 2025
Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes.
Journal: Current opinion in endocrinology, diabetes, and obesity
Published: November 10, 2025
Last Updated: 06/30/2026